000			03352nam a22003495i 4500
999			_c77872 _d77872 _x1
001			77872
003			ES-MaUEC
005			20230207040248.0
007			cr nn 008mamaa
008			141013s2014 gw | s |||| 0|eng d
020			_a9783319081625
024	7		_a10.1007/978-3-319-08162-5 _2doi
040			_dES-MaUEC
050		4	_aRC280.B8 _bS484 2014
100	1		_aSethi, Seema. _986850 _0Local
245	1	0	_amiRNAs and Target Genes in Breast Cancer Metastasis _cby Seema Sethi.
260			_aCham, Switzerland _bSpringer International Publishing _c2014
300			_a1 recurso en línea (VII, 78 p.) _b4 ilustraciones, 2 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aSpringerBriefs in Cancer Research
505	0		_aRole of miRNAs and their Target Genes in Breast Cancer Metastasis -- Molecular Pathogenesis of Breast Cancer and the Role of MicroRNAs -- Epidemiology, Risk Factors, Treatment and Prevention of Breast Cancer Metastases -- Clinical Perspectives: Breast Cancer Brain Metastasis -- Molecular targeted therapy for brain metastatic breast cancers: Current Updates.
520			_aThis SpringerBrief gives the latest research on the role of miRNAs in breast cancer metastasis. MicroRNAs (miRNAs) are recently described small endogenous noncoding RNAs implicated in the posttranscriptional control of gene expression. These tiny molecules are involved in developmental, physiologic phenomenon as well as pathologic processes including cancers. In fact, miRNAs have emerged as critical regulators of cancer progression, invasion and metastasis. This is mainly because a single miRNA can affect several downstream genes and signaling pathways with oncogenic or tumor suppressor actions depending on the target genes affected. Due to this multimodal downstream signaling effects, these small endogenous molecules hold great promise in metastasis prevention and treatment. Modulating the activity of miRNAs can provide opportunities for novel cancer interventions. Targeting miRNAs could become a novel prognostic and therapeutic strategy to prevent the future development of metastasis. Thus, miRNAs could also serve as a potential targets for anti-metastatic therapy. The book explores how the expression of miRNAs in the primary tumor could be silenced using antagomirs (chemically modified anti-miRNA oligonucleotides), which could prevent the development of metastasis; whereas once metastasis develops then it could be treated with miRNA mimics for inducing its expression for the treatment. Therefore, development of miRNA-based prophylactic therapies could serve as precision and personalized medicine against future development of metastasis of breast and other cancers.
650		7	_2embne _9182522 _aMamas _xCáncer
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-08162-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12843519 _b10-10-17 _c23-02-15
942			_2lcc _cLE
945			_aRC280.B8 S484 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11556420 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0